Cellectar Biosciences, Inc. — Q2 2015 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2015. Cellectar is a clinical-stage biopharmaceutical company developing phospholipid ether-drug conjugates for cancer treatment, diagnosis, and imaging. It reported no product revenue; the filing provides no revenue or gross-margin figures.
Key financial results
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Research and development | $1.383 million | $1.381 million | $3.027 million | $3.096 million |
| General and administrative | $818,000 | $960,000 | $1.761 million | $2.047 million |
| Restructuring costs | $91,000 | $205,000 | $91,000 | $222,000 |
| Total costs and expenses / operating loss | $2.291 million | $2.546 million | $4.879 million | $5.365 million |
| Net loss | $2.287 million | $2.086 million | $4.588 million | $5.029 million |
| Basic and diluted loss per share | $0.30 | $0.73 | $0.61 | $1.75 |
Cash flow and liquidity: Six-month operating cash use was $4.554 million, investing cash use was $34,000, and financing cash use was $2,000. Cash and cash equivalents fell to $4.833 million from $9.423 million at December 31, 2014. Management said available cash was expected to fund operations into Q4 2015; funding beyond then depends on raising additional capital or completing a strategic transaction. Current assets were $5.007 million versus current liabilities of $5.840 million. Restricted cash of $55,000 is held for a facility lease.
Debt and other liabilities: Notes payable totaled approximately $450,000, including $241,000 current and $209,000 long-term, relating to Wisconsin Economic Development Corporation loans. Capital lease obligations totaled approximately $12,000. A $4.885 million current derivative liability relates to warrants; total liabilities were $6.207 million. Stockholders’ equity was $2.373 million.
Changes and notable items
- For the first half, operating costs declined 9% year over year, while net loss narrowed 9%. Lower G&A (down 14%) and restructuring costs contributed; R&D declined 2%. Q2 net loss increased from the prior-year quarter despite lower total expenses, in part because the prior-year quarter included a larger warrant revaluation gain.
- First-half other income included a $292,000 noncash gain from revaluation of derivative warrants, compared with $519,000 in 2014. The derivative liability declined from $5.177 million at year-end to $4.885 million.
- Weighted-average shares used for loss per share were 7.563 million in 2015 versus 2.870 million in 2014. Accordingly, per-share comparisons are affected by the materially different share counts.
- Management attributed lower first-half G&A primarily to reduced stock-based compensation and consulting costs. Restructuring charges in 2015 related mainly to eliminated positions; 2014 charges primarily reflected closure of the Newton, Massachusetts office.
Business outlook, risks, and controls
- Funding and going concern: The company expects continuing operating losses and states that its ability to execute its plan depends on additional financing, a strategic transaction, or other funding. It had not entered negotiations for a financing transaction and cautioned that funding may not be available on acceptable terms or in time.
- Pipeline: I-131-CLR1404 was in a Phase I study for relapsed/refractory multiple myeloma, initiated in April 2015. Management anticipated evaluating the first cohort and starting the second in Q1 2016. CLR1601-PTX and CLR1800-GEM remained preclinical. The company was evaluating data from I-124-CLR1404 imaging studies.
- Regulatory development: The FDA classified CLR1502 as a combination product and assigned it to CDRH, requiring a new investigational application before a Phase I breast-surgery study. Cellectar was assessing the development pathway.
- Risks: Product candidates remain subject to clinical, regulatory, manufacturing, and commercialization uncertainty; the company may need to delay or reduce programs if it cannot raise capital. The filing says it has no products on the market and may never achieve profitability.
- Internal controls: Management concluded disclosure controls were not effective as of June 30, 2015 because of a material weakness in accounting for equity instruments. Remediation efforts were ongoing, with no assurance they would fully resolve the weakness.
- Other matters: The company reported no legal proceedings and said ordinary-course disputes were not expected to materially affect the financial statements. It was invoiced $418,000 by the University of Wisconsin-Madison for clinical-trial costs during the six months; $416,000 had been paid. No financial guidance beyond the stated cash runway was provided.
Important facts for investors to verify
- Whether Cellectar secured financing or other funding sufficient to continue operations beyond the expected Q4 2015 cash runway.
- Subsequent cash burn, clinical-trial spending, and progress and timing of the I-131-CLR1404 cohorts.
- The regulatory pathway and timing for CLR1502 following the FDA combination-product classification.
- Progress in remediating the material weakness and whether disclosure controls were later deemed effective.
- The valuation and potential dilution associated with the 6.604 million outstanding warrants and 895,119 stock options at June 30, 2015.